Apotex launches generic semaglutide injection in Canada

Canadian generic drugmaker Apotex said on May 14, 2026 that it has begun commercial sales of Apo-Semaglutide Injection, a generic equivalent of Novo Nordisk's Ozempic, with initial inventory already shipping to wholesalers and product expected on pharmacy shelves across Canada "within the coming weeks."^[1]

The company, headquartered in Toronto, described the launch as part of its effort to offer "high-quality, affordable" alternatives "aligned to all available brand-equivalent formats."^[1] Apotex did not disclose a price in its announcement, so how much Canadians will actually save compared with branded Ozempic is not yet known from the source material.^[1]

What was approved

Apo-Semaglutide Injection is approved in Canada in two prefilled pen formats. The 2 mg pen (0.68 mg/mL) delivers 0.25 mg or 0.5 mg doses, and the 4 mg pen (1.34 mg/mL) delivers 1 mg doses.^[1] The release does not mention a higher-strength pen, so the product as described covers the starting and maintenance doses up to 1 mg.^[1]

In Canada, the generic is indicated for once-weekly treatment of adults with type 2 diabetes to improve glycemic control, in combination with diet and exercise.^[1] It is not described as approved for weight management; that indication in the US belongs to Wegovy, which is the same molecule at different doses. Apotex said the pen is administered with "instructions for use consistent with brand-name semaglutide," which the company says should support "a smooth transition" for patients and prescribers.^[1]

The product was developed with Orbicular Pharmaceutical Technologies and went through "Health Canada's standard regulatory review for peptide medicines," according to the company.^[1] Semaglutide is a peptide, not a traditional small molecule, and regulators review copies of peptide drugs differently than they review biosimilars. The release does not spell out what data Apotex submitted.^[1]

"The launch of Apo-Semaglutide Injection reflects our Canadian roots and our dedication to making important treatment options more accessible to people across Canada," said Martin Arès, President of Apotex Canada.^[1] Apotex directed clinicians to the full Canadian product monograph for warnings, precautions, adverse reactions and monitoring requirements.^[1]

Why it matters for patients

For US patients, the immediate practical effect is none: this is a Canadian launch, and the Apotex announcement describes availability only in Canada.^[1] The company's news release does not address US approval, US patents, or any timeline for a US generic, so nothing about American availability can be concluded from it.

The development still matters for two reasons. First, it is a real-world test of whether a generic copy of a semaglutide pen can be manufactured, reviewed and distributed at scale in a major market — something that has not previously happened in a country with a drug regulator comparable to the FDA.^[1] Apotex's release does not itself claim a "first," but it is describing pharmacy-shelf availability of a generic semaglutide injection, not a compounded or unapproved copy.^[1]

Second, it sets a reference point for price. Generic entry usually pushes prices down, though the size of the drop depends on how many manufacturers compete and how national or provincial drug plans negotiate. Because Apotex did not publish pricing, that comparison is not yet possible.^[1]

It is also worth noting what this launch is not. It is not a weight-loss product in Canada by its stated indication, and it is not a version of the higher 2 mg Ozempic dose or of Wegovy's 2.4 mg dose based on the formats described.^[1] Cross-border purchasing, personal importation rules and whether a Canadian generic could legally be brought into the US are not addressed in the source and are governed by separate US rules.

What happens next

Apotex said product was shipping to wholesalers as of May 14, 2026, with pharmacy availability across Canada expected in the following weeks.^[1] Beyond that, the company gave no dated milestones — no additional strengths, no expanded indications, and no statement about other markets.^[1] Whether other manufacturers follow in Canada, and whether Canadian provincial formularies list the generic, are open questions that the announcement does not answer.^[1]